One-Step Differential Detection of OXA-48-Like Variants Using High-Resolution Melting (HRM) Analysis

Min Yi Lau 1, Kartini Abdul Jabar 1, Kek Heng Chua 2, Boon Pin Kee 2, Sasheela Sri La Sri Ponnampalavanar 3, Chun Wie Chong 4 and Cindy Shuan Ju Teh 1,∗

1 Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia; minyi@um.edu.my (M.Y.L.); kartini.abduljabar@ummc.edu.my (K.A.J.)
2 Department of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia; khchua@um.edu.my (K.H.C.); bpkee@um.edu.my (B.P.K.)
3 Department of Infectious Diseases, University Malaya Medical Centre, Kuala Lumpur 50603, Malaysia; sheela@ummc.edu.my
4 School of Pharmacy, Monash University Malaysia, Subang Jaya 47500, Malaysia; chong.chunwie@monash.edu
* Correspondence: cindysjteh@um.edu.my Tel.: +603-796-766-74

Received: 17 January 2020; Accepted: 12 March 2020; Published: 15 May 2020

Abstract: OXA-48-like carbapenemase gene remains a hidden threat, as different OXA-48 variants have varying presentations of susceptibility to antibiotics that might affect the treatment decisions. Rapid detection and differentiation of OXA-48-like carbapenemase genes are critical for targeted treatment and infection control. In this study, we aimed to develop high-resolution melting (HRM) analysis for the differentiation of OXA-48 variants. HRM analysis is a post-polymerase chain reaction (post-PCR) method for identification of small variations in nucleic acid sequences based on the PCR dissociation curve. A total of 82 bacterial strains, which consisted of Enterobacteriaceae and non-Enterobacteriaceae, were collected from a tertiary teaching hospital. The sensitivity and specificity of the assay were determined, and the developed assay was evaluated using the collected isolates against conventional-sequencing method. Overall, the developed assay was able to detect isolates that harboured OXA-48 and OXA232/OXA-181 by showing two distinct peaks at 81.1 ± 0.2 °C and 82.1 ± 0.2 °C, respectively. The detection limit of the assay was 1.6 x 10⁶ ng/µl for OXA-48 and 1.8 x 10⁷ ng/µl for OXA-232/OXA-181. This assay showed 100% specificity when evaluated on a panel of 37 isolates comprised of different species of bacteria and yeasts. When the assay with isolates collected in the year 2016 was first evaluated, the assay showed comparable results with conventional PCR-sequencing method where 34 OXA-48 and OXA-232/OXA-181 were detected. By using HRM analysis, the presence of OXA-48-like variants could be easily identified within 3 hours from the pure culture.

Keywords: carbapenem-resistant Klebsiella pneumoniae; Enterobacteriaceae; OXA-48; HRM; real-time PCR

1. Introduction

The prevalence of carbapenem-resistant Enterobacteriaceae (CRE), especially those harbouring OXA-48-like carbapenem hydrolysing class D β-lactamases, has increased at an alarming rate [1]. OXA-48 is a plasmid borne enzyme that is only detected in Enterobacteriaceae, and is commonly associated with Klebsiella pneumoniae (K. pneumoniae) [1]. The first OXA-48 carbapenemase gene was
identified in a *K. pneumoniae* isolate from Istanbul, Turkey in 2001 and subsequently disseminated in many countries including India, North Africa, and Europe [1,2].

In the past decade, several OXA-48-like variants have been described such as OXA-48, OXA-232, OXA-181, OXA-162, OXA-163, OXA-244, and OXA-245 [3]. Each variant differs from OXA-48 by one to five amino acid substitution or deletion, which results in different hydrolytic profiles. For example, OXA-232 exhibited five amino acid substitutions compared to OXA-48 but differed from OXA-181 by just one point mutation [1]. However, not all OXA-48-like variants have been reported in Asia. The most common detected OXA-48-like variants in Asia are OXA-48, OXA-232, and OXA-181. In Malaysia, only OXA-48 and OXA-232 were previously reported [4,5]. Nonetheless, recent studies showed that the cases caused by OXA-48 carbapenemase gene had increased drastically [4,5].

OXA-48 hydrolysed penicillin at a high level but was low in carbapenem, and it showed weak activity against expanded-spectrum cephalosporin [1]. On the other hand, OXA-181 showed higher ability to hydrolyse carbapenems, while OXA-232 possessed lower hydrolytic ability to carbapenems as compared to OXA-48 and OXA-181[6]. Furthermore, OXA-232 hydrolysed all penicillin (with the exception of temocillin) more efficiently than OXA-48 and OXA-181 [7]. This suggested that different OXA-48-like variants have different presentation of susceptibilities to antibiotics, which might affect the treatment decisions. Rapid and accurate detection of OXA-48-like carbapenemases are vital to control their dissemination. The current method for differential detection of OXA-48-like variants harboured by the carbapenem-resistant *Enterobacteriaceae* is by polymerase chain reaction (PCR), followed by direct sequencing to identify the point of mutations. Due to the high level of similarity among OXA-48-like variants, DNA sequencing is the currently preferred method to identify OXA-48 variants with high accuracy. However, the major drawback of the method is long turn-around time. High-resolution melting (HRM) analysis has been used for rapid detection of nucleotide polymorphisms within PCR products based on their melting curve. This method is shown to be sensitive and specific [8]. To address the limitation of conventional method, we have developed a HRM assay for rapid detection and differentiation of OXA-48-like carbapenemase gene.

2. Results

2.1. Detection and Differentiation of OXA-48 and OXA-232/OXA-181 by Real-Time PCR with HRM Analysis

In the 298-bp region amplified by the designed primers, OXA-48 differs from OXA-181 and OXA-232 by four and five amino acids substitutions, respectively, while OXA-181 and OXA-232 only differ by one nucleotide substitution at position 642 (A to T). The derivative of melt curves produced by HRM software showed two distinct peaks (Figure 1), representing OXA-48 and OXA-232/OXA-181 at temperature of 81.1 ± 0.2 °C and 82.1 ± 0.2 °C, respectively. The aligned melt curves were shown in Figure 2. No amplification was observed for the negative control (CRE-192).

2.2. Sensitivity and Specificity Test

The detection limit of OXA-48 was found to be 1.6 x 10⁴ ng/µl, while OXA-232/OXA-181 was 1.8 x 10² ng/µl. This newly developed assay successfully detected OXA-48-like variants from all 17 *Enterobacteriaceae*. No amplification was observed for Methicillin-resistant *Staphylococcus aureus* (MRSA), *Candida albicans*, *Haemophilus influenzae*, and *Acinetobacter baumannii* (Figure 3). This assay successfully differentiated the OXA-232-producing *E. coli* isolate from other OXA-48 isolates and yielded 100% specificity. These observations suggested that this newly developed HRM assay was effective in identifying the presence of OXA-48-like gene and differentiating common OXA-48-like variants in CRE (OXA-48 and OXA-232/OXA-181).

2.3. Evaluation of Real-Time PCR assay with HRM Analysis Using CRE Isolates in 2016

Among the 45 isolates collected in 2016, 34 harboured OXA-48-like gene based on real-time PCR assay with HRM analysis and conventional PCR. According to the HRM analysis, the OXA-48
positive isolates were further resolved into two variants based on the two peaks observed at 81.1 ± 0.2 °C (31 isolates) and 82.1 ± 0.2 °C (3 isolates). All the 31 isolates were OXA-48, whereas the three isolates were OXA-181/ OXA-232 (Table 1). This finding was in agreement with sequencing results where three of the isolates carried different amino acids at position 104, 110, 175, 179, and 222 than other isolates.

Overall, the detection time required for HRM analysis from pure culture to the final results is about three hours, which is great improvement from the conventional PCR-sequencing method, which requires turnaround time of three days.

Figure 1. Derivative melt curves of OXA-48 (blue) and OXA-232/OXA-181 (green). The Tm values for variant 1 and variant 2 were 81.1 ± 0.2 °C and 82.1 ± 0.2 °C respectively.

Figure 2. Aligned melt curves of OXA-48 (blue) and OXA-232/OXA-181 (green).
Figure 3. Derivative melt curve of OXA-48-like carbapenemase gene detection from different species. Amplification peak was observed from *Enterobacteriaceae*, which carried OXA-48 (yellow) and OXA-232 (grey) carbapenemase gene, whereas no peak was showed from other species including *Candida albicans*, *Haemophilus influenzae*, *Staphylococcus aureus*, and *Acinetobacter baumannii*, which do not produce OXA-48-like carbapenemase gene.

Table 1. Evaluation of high-resolution melting (HRM) analysis using carbapenem-resistant *Enterobacteriaceae* (CRE) isolates collected in 2016.

| Organisms            | Strains ID | Conventional PCR-Sequencing | HRM Analysis          |
|----------------------|------------|----------------------------|-----------------------|
| *Klebsiella pneumoniae* | CRKP 30    | OXA-232                    | OXA-232/OXA-181       |
| *Klebsiella pneumoniae* | CRKP 37    | OXA-232                    | OXA-232/OXA-181       |
| *Klebsiella pneumoniae* | CRKP 38    | OXA-181                    | OXA-232/OXA-181       |

3. Discussion

CRE was frequently reported across the Asia-Pacific region. In the past decade, OXA-48-like carbapenemase gene was the most prevalent in Europe, Mediterranean, and North Africa [9]. Recently, OXA-48-like carbapenemase gene has emerged and spread in Southeast-Asia, including Malaysia [5], Singapore [10], Brunei [11], Thailand [12], and Vietnam [13]. Here, we identified the prevalence of OXA-48-like carbapenemase gene in Malaysia in recent years. OXA-48 has been the most common carbapenemase gene detected in our hospital. The first report of OXA-48-like carbapenemase gene from our hospital was in 2013 [5]. Among forty-five CRKP strains investigated in this study, 75.5% harboured *bla*OXA-48-IA. Although OXA-48-like carbapenemases has weak hydrolytic ability towards carbapenem, high level of carbapenem resistance may occur when combined with other mechanisms such as loss of porin on the outer membrane [9]. Furthermore, it has been reported that different OXA-48-like variants present different susceptibility to antibiotics [6]. Therefore, rapid detection of OXA-48 and its variants is important to control their dissemination and provides a reference for better treatment decision.

Phenotypic tests have been used to detect carbapenem resistance. However, OXA-48 and its variants have different susceptibility towards broad-spectrum cephalosporins and carbapenem [1]. Identification of OXA-48-like carbapenemase by phenotypic assay was difficult to interpret and most likely was underestimated due to the low level resistance to carbapenem [9]. On the other hand,
conventional phenotypic tests were time-consuming and low in sensitivity and specificity in OXA-48 detections [14]. Therefore, molecular techniques, particularly PCR, remain as the gold standard for identification of OXA-48 [14,15]. PCR screening for OXA-48 has been reported in several studies either using single targeted PCR assays or multiplex PCR assays together with detection of other carbapenemase genes, but not in differentiation of OXA-48-like carbapenemase gene variants [2,16,17]. Commercial kit such as Check-Direct carbapenemase-producing Enterobacteriaceae (CPE) assays (Check-Points, Wageningen, the Netherlands), Xpert Carba-R (Cepheid, Sunnyvale, California), EazyPlex Superbug ID complete A/B (Amplex, Giessen, Germany), and the very recent point-of-care GenePOC technology (GenePOC, Quebec City, Canada) have also been developed and widely used for detection of carbapenemase gene (KPC, NDM, VIM, IMP-1, and OXA-48) [18–21]. However, none of these assays could differentiate OXA-48 variants. Indeed, single nucleotide mutation among OXA-48 and its variants are indistinguishable using conventional PCR.

In this study, our newly developed real-time PCR assay with HRM analysis not only detected the presence of OXA-48, the method also differentiated OXA-48 from OXA-232/OXA-181 based on the melt curve pattern. HRM analysis is frequently used for genotyping and detection of single nucleotide polymorphisms [22]. It has been used as a tool for rapid detection and differentiation of carbapenemase gene variants such as KPC gene variants [23,24]. More recently, Hemarajata et al. have developed a similar real-time PCR assay with HRM analysis to detect and differentiate OXA-48-like variants [25]. Although the assay developed by Hemarajata et al. could differentiate OXA-232 and OXA-181 from other OXA-48-like genes, the use of LunaProbe has directly increased the cost of test. As compared to our newly developed HRM assay, the cost of our assay will be cheaper and affordable for most of the molecular laboratory. In general, HRM analysis is less tedious and more rapid compare to conventional PCR-sequencing method. Simpler procedure and lesser step could significantly reduce cross contamination and human error. However, as HRM utilized specific primers that targeted flanking region of the targeted region (usually less than 250 base pair), it might not be able to capture new mutations that fall outside the targeted regions. In contrast, PCR-sequencing that does not have limitations on product size could detect the new mutation more efficiently.

The OXA HRM assay has demonstrated high sensitivity and specificity in detecting OXA-48-like carbapenemase gene in all previously characterized OXA-48-like isolates. In addition, this assay was specific in the detection of OXA-48-like carbapenemases. For instance, other OXA-type carbapenemases such as OXA-23-like carbapenemases in Acinetobacter baumannii did not yield positive result. For differentiation of the three most prevalent OXA-48 variants, only two melting curves were shown. The nucleic acid sequences of OXA-232 and OXA-181 only differ by a single base pair at position 642 (A to T), an amino acid mutation, causing the melting curve incomparable [7]. However, sequencing is still required needed to distinguish OXA-232 and OXA-181 since they have different hydrolytic profiles, and this has been identified as the limitation in the study.

Before the development of HRM analysis assay, differentiation of OXA-48-like carbapenemase gene variants was usually done by sequencing after PCR amplification, which required more than two days to obtain the results. HRM analysis has significantly shortened the process of analysing OXA-48-like variants into three hours. In addition, direct characterization of OXA-48-like carbapenemase variants in a single closed system has reduced the risk of contamination. However, we acknowledge that the lack of other OXA-48-like variants isolates to validate this newly developed assay is the major caveat of this study.

4. Materials and Methods

4.1. Ethics Approval

This study has been approved by UMMC Medical Ethics Committee (MEC ID: 20154-1249).

4.2. Bacterial Strains
All bacterial strains were isolated from various clinical specimens such as blood, urine, pus, tissue, fluid, sputum, and swab samples from a tertiary teaching hospital. They were revived and checked for purity before commencement of benchwork. All the isolates were then subjected to blaOXA-48 genes detection by PCR with reported primers sequences [2].

4.3. Development of Real-Time PCR Assay with HRM Analysis

OXA-48-like sequences were retrieved from the NCBI database as a reference for primers design. A set of primers that ampliﬁed 298-bp region of the conserved region flanking the variable sites was designed and checked by Primer BLAST. Real-time PCR with HRM analysis was performed in 20 µl reaction, which contained 10 µl of MeltDoctor™ HRM Master Mix (Applied Biosystems Inc, USA), 0.3 µM of primer HRM OXA-48 F (5′-TCGGGCAATGTTGGAGTATT-3′), 0.3 µM of primer HRM OXA-48 R (5′-GCCCTAAAACCATCCGATGTG-3′), and 1 µl of template DNA (~20 ng/µl). The real-time PCR with HRM was carried out in a 7500 Fast real-time PCR system (Applied Biosystems Inc, USA). The cycling parameter was set at 95 °C for 10 min (enzyme activation), followed by 40 cycles of amplification, including 95 °C for 15 s (denature) and 60 °C for 1 min (annealing). Next, melting step or dissociation step were carried out at 95 °C for 10 s (denature), 60 °C for 1 min (annealing), 95 °C for 15 s (high-resolution melting), and final annealing at 60 °C for 15 s. The melting curve proﬁle was recorded and analyzed using High Resolution Melt software for Windows® version 3.0.1. The condition for HRM analysis was tested by using the two control strains (CRE-48 and CRE-232, which harboured OXA-48 and OXA-232, respectively). One non-OXA-48 producer (CRE-192) was used as the negative control. The presence of OXA-48-like carbapenemase genes was identiﬁed based on the melt curve pattern.

4.4. Sensitivity and Speciﬁcity Test

Genomic DNA of previously identify CRE-48 and CRE-232, which harboured OXA-48 and OXA-232 genes, respectively, were extracted and quantiﬁed using a NanoPhotometer™ (Implen, Germany). The DNA was then 10-fold serially diluted and subjected to real-time PCR assay with HRM analysis.

Speciﬁcity test was performed on a panel of strains, which were comprised of 17 Enterobacteriaceae (Serratia marcescens, Escherichia coli, Enterobacter aerogenes, Enterobacter cloacae, Klebsiella pneumoniae, and Citrobacter freundii), 15 non-Enterobacteriaceae (Methicillin-resistant Staphylococcus aureus (MRSA), Candida albicans, and Haemophilus inﬂuenzae), and ﬁve Acinetobacter baumannii isolates with OXA-23 carbapenemase genes. The presence of OXA-48-like gene in the 17 Enterobacteriaceae was previously conﬁrmed by PCR. Among the 17 Enterobacteriaceae, one E. coli isolate was conﬁrmed to be OXA-232-producer based on sequencing data. All the isolates were revived and subjected to the developed assay.

4.5. Further Evaluation of the Assay Using the CRE Isolates Collected from January 2016 to December 2016

The developed assay was further evaluated using CRE isolates newly collected from the UMMC. In total, 45 isolates were collected within a duration of 12 months and the isolates were subjected to conventional PCR-sequencing and real-time PCR assay with HRM analysis for identiﬁcation of the blaOXA-48 variants.

5. Conclusions

In conclusion, we have successfully developed a HRM analysis assay that is able to detect and distinguish OXA-48-like carbapenemase gene variants in a rapid and effective way. This assay requires little interpretation, and we believe that it will be important in OXA-48 carbapenemase gene dissemination control and epidemiology investigations.
Author Contributions: Conceptualization, K.H.C. and C.S.J.T.; Data curation, K.A.J. and C.W.C.; Formal analysis, C.W.C.; Funding acquisition, C.S.J.T.; Investigation, S.P. and C.S.J.T.; Methodology, M.Y.L., K.H.C., B.P.K., and C.S.J.T.; Project administration, M.Y.L. and C.S.J.T.; Resources, K.A.J. and S.P.; Supervision, K.A.J. and K.H.C.; Validation, K.H.C. and B.P.K.; Writing—original draft, M.Y.L. and B.P.K.; Writing—review and editing, M.Y.L. and C.S.J.T. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Malaysia Toray Science Foundation, grant number PV051-2018, and Institut Mérieux – Malaysian Society of Infectious diseases & Chemotherapy (MSIDC), grant number IF045-2018.

Acknowledgments: We thank University of Malaya for support and facilities.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. *J Antimicrob Chemother*. 2012;67(7):1597-606.
2. Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 2004;48(1):15-22.
3. Evans BA, Amyes SG. OXA-β-lactamases. *Clin Microbiol Rev*. 2014;27(2):241-63.
4. Al-Marzooq F, Ngeow YF, Tay ST. Emergence of *Klebsiella pneumoniae* producing dual carbapenemases (NDM-1 and OXA-232) and 16S rRNA methylase (armA) isolated from a Malaysian patient returning from India. *Int J Antimicrob Agents*. 2015;45(4):445-6.
5. Low YM, Yap PSX, Abdul Jabar K, Ponnamalavanan S, Karunakaran R, et al. The emergence of carbapenem resistant *Klebsiella pneumoniae* in Malaysia: correlation between microbiological trends with host characteristics and clinical factors. *Antimicrob Resist Infect Control*. 2017;6(1):5.
6. Oueslati S, Nordmann P, Poirel L. Heterogeneous hydrolytic features for OXA-48-like β-lactamases. *J Antimicrob Chemother*. 2015;70(4):1059-63.
7. Potron A, Rondinaud E, Poirel L, Belmonte O, Boyer S, et al. Genetic and biochemical characterisation of OXA-232, a carbapenem-hydrolysing class D β-lactamase from *Enterobacteriaceae*. *Int J Antimicrob Agents*. 2013;41(4):325-9.
8. Reed GH, Wittwer CT. Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. *Clin Chem*. 2004;50(10):1748-54.
9. van Duin D, Doi Y. The global epidemiology of carbapenemase-producing *Enterobacteriaceae*. *Virulence*. 2017;8(4):460-9.
10. Balm MN, Ngan G, Jureen R, Lin RT, Teo JW. OXA-181-producing *Klebsiella pneumoniae* establishing in Singapore. *BMC Infect Dis*. 2013;13(1):58.
11. Momin MHFA, Liakopoulos A, Phee LM, Wareham DW. Emergence and nosocomial spread of carbapenem-resistant OXA-232-producing *Klebsiella pneumoniae* in Brunei Darussalam. *J Glob Antimicrob Resist*. 2017;9:96-9.
12. Lunha K, Chanawong A, Lulitanond A, Wilailuckana C, Charoensri N, et al. High-level carbapenem-resistant OXA-48-producing *Klebsiella pneumoniae* with a novel OmpK36 variant and low-level, carbapenem-resistant, non-porin-deficient, OXA-181-producing *Escherichia coli* from Thailand. *Diagn Microbiol Infect Dis*. 2016;85(2):221-6.
13. Tada T, Tsuchiya M, Shimada K, Nga TTT, Phu TT, et al. Dissemination of carbapenem-resistant *Klebsiella pneumoniae* clinical isolates with various combinations of carbapenemases (KPC-2, NDM-1, NDM-4, and OXA-48) and 16S rRNA Methyelases (RmtB and RmtC) in Vietnam. *BMC Infect Dis*. 2017;17(1):467.
14. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing *Enterobacteriaceae*. *Emerg Infect Dis*. 2011;17.
15. Hanson ND. Molecular diagnostics could help in coping with hidden β-lactamases. *Microbe*. 2010;5(8):333-9.
16. Poirel L, Bonnin RA, Nordmann P. Genetic features of the widespread plasmid coding for the carbapenemase OXA-48. *Antimicrob Agents Chemother*. 2012;56(1):559-62.
17. Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. *Diagn Microbiol Infect Dis*. 2011;70(1):119-23.
18. Huang T-D, Bogaerts P, Ghilani E, Heinrichs A, Gavage P, et al. Multicentre evaluation of the Check-Direct CPE® assay for direct screening of carbapenemase-producing Enterobacteriaceae from rectal swabs. *J Antimicrob Chemother*. 2015;70(6):1669-73.
19. Perry K, Daniels J, Reddy S, Kallen A, Halpin A, et al. Direct detection of carbapenem-resistant organisms from environmental samples using the GeneXpert molecular diagnostic system. *MSphere*. 2018;3(4):e00113-18.
20. García-Fernández S, Morosini M-I, Marco F, Gijón D, Vergara A, et al. Evaluation of the eazyplex® SuperBug CRE system for rapid detection of carbapenemases and ESBLs in clinical Enterobacteriaceae isolates recovered at two Spanish hospitals. *J Antimicrob Chemother*. 2015;70(4):1047-50.
21. Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria. *Clin Infect Dis*. 2019;69(Supplement_7):S521-S8.
22. Liew M, Pryor R, Palais R, Meadows C, Erali M, et al. Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. *Clin Chem*. 2004;50(7):1156-64.
23. Roth AL, Hanson ND. Rapid detection and statistical differentiation of KPC gene variants in Gram-negative pathogens by use of high-resolution melting and ScreenClust analyses. *J Clin Microbiol*. 2013;51(1):61-5.
24. Monteiro J, Widen RH, Pignatari AC, Kubasek C, Silbert S. Rapid detection of carbapenemase genes by multiplex real-time PCR. *J Antimicrob Chemother*. 2012;67(4):906-9.
25. Hemarajata P, Yang S, Hindler JA, Humphries RM. Development of a novel real-time PCR assay with high-resolution melt analysis to detect and differentiate OXA-48-like β-lactamases in carbapenem-resistant Enterobacteriaceae. *Antimicrob Agents Chemother*. 2015;59(9):5574-80.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).